MoneyWorks4Me

Concord Drugs - Quaterly Results

28 May 2026 Evaluate
The total revenue hovered 346.27% to Rs. 355.63 millions for the March 2026 quarter as against Rs. 79.69 millions during the corresponding quarter last year.The company almost doubled its revenue to Rs. 5.17 millions  from Rs. 0.08 millions in the quarter ended March 2026.Operating profit for the quarter ended March 2026 rose to 14.30 millions as compared to 9.31 millions of corresponding quarter ended March 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 355.63 79.69 346.27 758.83 369.46 105.39 758.83 369.46 105.39
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT 14.30 9.31 53.60 42.64 37.77 12.89 42.64 37.77 12.89
Interest 3.45 5.35 -35.51 14.59 17.18 -15.08 14.59 17.18 -15.08
PBDT 10.85 3.96 173.99 28.05 20.59 36.23 28.05 20.59 36.23
Depreciation 3.50 3.75 -6.67 13.57 14.18 -4.30 13.57 14.18 -4.30
PBT 7.35 0.21 3400.00 14.48 6.41 125.90 14.48 6.41 125.90
TAX 2.18 0.13 1576.92 4.11 3.46 18.79 4.11 3.46 18.79
Deferred Tax 0.05 0.19 -73.68 -0.02 1.56 -101.28 -0.02 1.56 -101.28
PAT 5.17 0.08 6362.50 10.37 2.95 251.53 10.37 2.95 251.53
Equity 131.75 100.00 31.75 131.75 100.00 31.75 131.75 100.00 31.75
PBIDTM(%) 4.02 11.68 -65.58 5.62 10.22 -45.03 5.62 10.22 -45.03
Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..